COVID-19 forces sponsors to take new approach for assessing trial support models.
Statistical methods used via this technique in centralized monitoring.
Following COVID-19, companies are focused on solutions offering the latest technology and most value to patients.
Although there are much larger problems in clinical research, storing obsolete study records is a totally unnecessary cost.
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Economic challenges combined with increased responsibility for clinical trial workers has shifted talent recruitment.
A focus on the position of law for e-signatures, their benefits, and the role of Clinical Research Malaysia in educating the industry on the practicality of e-signature.
Findings from a Tufts study examining the effects of COVID-19 on clinical trials.
The use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.
Though artificial intelligence has yet to achieve its full potential, meaningful strides are still being made across the drug discovery funnel.
Leveraging a “diversity by design” approach can build patient narratives and optimize protocols from the onset.
Harmonization could turn the continent into an established site for clinical research and laboratories.
Approaches sponsors, CROs, and investigators can take from the DMD experience.
Outlining new approaches and resources to help ignite progress in this area.
In this eBook learn about varying categorizations and how they impact combination product registrations in the US and EU markets.
Case study shows how one CRO ensured high-quality, consistent data in a difficult therapeutic area.
Work across varying therapeutic areas and new technology among reasons why CROs are qualified to advance model.
Wednesday, October 12, 2022 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Real-world-data (RWD) leads to real-world results. Learn how RWD & patient tokenization are streamlining clinical trials and ensuring successful results.
Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.
Changes predicted to change the face of clinical research in 2021.
Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Integrated approaches can help enhance recruitment plans.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
The careful selection of sensor technology prioritized in clinical trials, considering regulatory compliance, data security, device characteristics, and the specific needs of the trials for successful and confident implementation.
In an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
Study seeks to understand how different forms of data meet the needs of researchers.
Implementing disclosure and data transparency policies and procedures represents an opportunity for sponsors, rather than an obligation.
Improving the site-sponsor relationship can get trials off on the right foot and on a path for success.
Trust-based relationships form the foundation for successful trial management.